BPC-157 vs Thymosin Beta-4
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
BPC-157 and Thymosin Beta-4 are both healing regenerative peptides that come up together constantly. This is a side-by-side comparison on the data that actually matters — evidence tier, FDA status, human trials, and how to source each safely — not hype. It is for research and educational purposes only.
BPC-157 vs Thymosin Beta-4: side-by-side
| BPC-157 | Thymosin Beta-4 | |
|---|---|---|
| Evidence tier | Tier 3 | Tier 2 |
| FDA status | Not FDA Approved | Investigational |
| Human RCTs | 0 | 4 |
| Subjects enrolled | 0 | 400 |
| Animal studies | 60 | 40 |
| Category | healing regenerative | healing regenerative |
| Half-life | Reported short plasma half-life (minutes) in animal models; tissue effects appear longer-lasting. | Estimated multi-hour half-life. |
| Community logs | 1 | 0 |
Key differences
Thymosin Beta-4 rests on stronger human evidence (Tier 2) than BPC-157 (Tier 3) — that means more confidence its observed effects are real rather than artefacts of weaker study designs. Neither is FDA approved for human use — both are not fda approved / investigational and treated as research compounds in the US.
BPC-157 has 0 human trials on record (0 subjects) versus Thymosin Beta-4's 4 (400 subjects). Evidence tiers are a shorthand for how strong that human data is — see our guide to understanding peptide evidence tiers for how to weigh them.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Preclinical research suggests it promotes angiogenesis and tissue repair. As of 2026 it has not been studied in published human randomized controlled trials and is not FDA-approved; the evidence… Full BPC-157 breakdown →
What is Thymosin Beta-4?
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide central to actin regulation, cell migration, and tissue repair. Full-length thymosin beta-4 (distinct from the TB-500 fragment marketed in research-chemical channels) has been evaluated in early human clinical trials for indications such as dry eye and… Full Thymosin Beta-4 breakdown →
Where to buy BPC-157 or Thymosin Beta-4 safely
Both are sold by research-chemical suppliers, not pharmacies, so the source matters as much as the compound. Before buying either, vet sellers on third-party lab testing and enforcement history in the ranked directory of trusted peptide sellers — or jump straight to vetted sources for BPC-157 or Thymosin Beta-4. PeptidesHub does not sell either compound.
Frequently asked questions
BPC-157 and Thymosin Beta-4 are both healing regenerative peptides. Thymosin Beta-4 rests on stronger human evidence (Tier 2) than BPC-157 (Tier 3) — that means more confidence its observed effects are real rather than artefacts of weaker study designs. Neither is FDA approved for human use — both are not fda approved / investigational and treated as research compounds in the US. See each compound's full evidence breakdown for the underlying studies.